4001ÀϰٻãÍøÕ¾

±±¾©»ùÒò×éËù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©Õ¹ÏÖÂí¶µÁåËáÍ»±äÌØÕ÷¿ÉÓÃÓÚʶ±ðÉÏÄò·Äò·ÉÏÆ¤°©µÍΣº¦ÑÇÐÍ

¡¡¡¡¿ËÈÕ £¬ÖпÆÔº±±¾©»ùÒò×éÑо¿Ëù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©´ÈάÃôÑо¿×éÓë±±¾©´óѧµÚÒ»Ò½ÔºÖÜÀûȺ×éºÏ×÷ £¬Õ¹ÏÖµ¥ºËÜÕËáÍ»±äÌØÕ÷µÄ·Ö×Ó·ÖÐͼ°Âí¶µÁåËá(AA)Ïà¹ØÍ»±äÌØÕ÷¿É×÷Ϊ·Ö×Ó±ê¼ÇÎïɸѡÉÏÄò·Äò·ÉÏÆ¤°©µÍΣº¦ÑÇÐͲ¢¾ßÓÐʵÏÖÎÞ´´¼ì²âµÄDZÁ¦ £¬¸ÃÏîÑо¿Ð§¹ûÒÔ¡°Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma¡±ÎªÌâÔÚѧÊõÆÚ¿¯TheranosticsÔÚÏß½ÒÏþ ¡£

¡¡¡¡Äò·ÉÏÆ¤°©ÊÇ×î³£¼ûµÄÃÚÄòϵͳ¶ñÐÔÖ×ÁöÖ®Ò» £¬ÆäÖÐԼĪ90%-95%µÄÄò·ÉÏÆ¤°©±¬·¢ÓÚ°òë× £¬ÉÏÄò·Äò·ÉÏÆ¤°©(UTUC)½öÕ¼5%-10% ¡£µ«ÔÚ¶«ÑǵØÇø £¬ÓÉÓÚÖвÝÒ©µÄÊ¢ÐÐ £¬UTUCµÄÕ¼±È×î¸ßÁè¼Ý30% ¡£ÓÐÑо¿ÒѾ­Ö¤ÊµAA̻¶ÊÇUTUC¼°ÖвÝÒ©Éö²¡¸ß·¢µÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ £¬±¾Ñо¿Ö¼ÔÚ̽Ë÷ÖйúUTUCµÄÁÙ´²·Ö×ÓÌØÕ÷¼°Ç±ÔÚµÄÕïÁÆË¼Ð÷ ¡£Ñо¿Ö°Ô±¶Ô90ÀýUTUCÑù±¾¾ÙÐÐÈ«»ùÒò×é²âÐò £¬²¢Æ¾Ö¤Ö×ÁöÌåϸ°ûÍ»±äÊý¾Ý¿â£¨Catalogue of Somatic Mutations in Cancer£©ÒÑÆÊÎöµÄÍ»±äÌØÕ÷¶ÔËùÓÐÑù±¾¾ÙÐоÛÀàÆÊÎö £¬·¢Ã÷AAÍ»±äÌØÕ÷(signature 22)Õ¼±È¸ßµÄUTUC»¼Õß(¼´AA SigÑÇÀà)AAÖвÝҩ̻¶±ÈÀý½Ï¸ß £¬¸ÃÑÇ×éµÄÅ®ÐÔ»¼Õß±ÈÀý¸ß £¬³£ÌåÏֶಡÔîÒÔ¼°½Ï²îµÄÉö¹¦Ð§ £¬µ«ÉúÑÄÆÊÎö·¢Ã÷AA SigÑÇÀ໼ÕßÔ¤ºó½Ïsignature 22Õ¼±ÈµÍ(No-AA Sig)µÄ¸üºÃ ¡£AA SigÑÇÀà¶àÔîÐÔ»¼ÕߵĶàÑù±¾»ùÒò×鹨ÁªÆÊÎöÍÆ²â £¬ÇøÓò°©»¯ºÍ¹Üǻݪֲ¿ÉÄÜÅäºÏÔö½ø¸ÃÑÇÀ໼ÕßµÄÖ×Áö¶à²¡ÔîºÍ°òë׸´·¢ ¡£±ðµÄ £¬AA SigÑÇÀàÖ×ÁöÌåÏÖ³ö½Ï¸ßµÄÍ»±ä¸ººÉ¡¢Õ¹ÍûÖ×Áö¿¹Ô­ÊýÄ¿ºÍÃâÒßϸ°û½þÈó £¬ÌåÏÖAA SigÑÇÀ໼Õß¿ÉÄÜÊÇÖ×ÁöÃâÒßÖÎÁƵÄDZÔÚÈËȺ ¡£×îºó £¬¸ÃÑо¿·¢Ã÷ʹÓõͲãÊýÈ«»ùÒò×é²âÐò £¬ÔÚÄòÒºÉÏÇåϸ°ûÓÎÀëDNA(cfDNA)ÖÐÈÔ¿ÉÕ¹ÍûAA SigÑÇÐÍ ¡£ÉÏÊöЧ¹ûÅú×¢AA SigÊÇÒ»ÀàµÍΣΣº¦Ö×ÁöÀàÐÍ £¬²¢ÓÐͨ¹ýÔÚÄòÒºÖоÙÐÐÍ»±äÌØÕ÷¼ì²âʵÏÖÔçÆÚÕï¶ÏºÍ¼à²âµÄDZÁ¦ ¡£

¡¡¡¡¸ÃÑо¿»ñµÃÁË4001ÀϰٻãÍøÕ¾Õ½ÂÔÐÔÏȵ¼¿Æ¼¼×¨Ïî¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§ÒÔ¼°¹ú¼ÒÖØµãÑз¢ÍýÏëµÈ»ù½ð×ÊÖú ¡£

¡¡¡¡ÎÄÕÂÁ´½Ó

4001Àϰٻãnet(¼¯ÍÅ)NO.1¹Ù·½ÍøÕ¾

Âí¶µÁåËᣨAA£©Í»±äÌØÕ÷×÷ΪһÖÖɸѡ¹¤¾ß £¬Ê¶±ð¾ßÓÐÖÎÁÆÒâÒåµÄµÍΣº¦UTUCÑÇÀà

¸½¼þÏÂÔØ£º
ÍøÕ¾µØÍ¼